- Home
- CTO vs CRMD Comparison
CTO vs CRMD Comparison
Compare CTO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- CRMD
- Stock Information
- Founded
- CTO 1902
- CRMD 2006
- Country
- CTO United States
- CRMD United States
- Employees
- CTO N/A
- CRMD N/A
- Industry
- CTO Real Estate Investment Trusts
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- CRMD Health Care
- Exchange
- CTO Nasdaq
- CRMD Nasdaq
- Market Cap
- CTO 589.6M
- CRMD 973.3M
- IPO Year
- CTO N/A
- CRMD 2010
- Fundamental
- Price
- CTO $17.55
- CRMD $11.59
- Analyst Decision
- CTO Strong Buy
- CRMD Strong Buy
- Analyst Count
- CTO 3
- CRMD 7
- Target Price
- CTO $22.33
- CRMD $17.33
- AVG Volume (30 Days)
- CTO 368.0K
- CRMD 2.5M
- Earning Date
- CTO 07-29-2025
- CRMD 08-13-2025
- Dividend Yield
- CTO 8.66%
- CRMD N/A
- EPS Growth
- CTO N/A
- CRMD N/A
- EPS
- CTO N/A
- CRMD 0.28
- Revenue
- CTO $132,203,000.00
- CRMD $82,553,827.00
- Revenue This Year
- CTO $20.11
- CRMD $238.38
- Revenue Next Year
- CTO $8.51
- CRMD $53.52
- P/E Ratio
- CTO N/A
- CRMD $41.79
- Revenue Growth
- CTO 17.48
- CRMD N/A
- 52 Week Low
- CTO $16.12
- CRMD $3.61
- 52 Week High
- CTO $21.15
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- CTO 42.19
- CRMD 39.28
- Support Level
- CTO $17.10
- CRMD $12.14
- Resistance Level
- CTO $17.71
- CRMD $17.43
- Average True Range (ATR)
- CTO 0.38
- CRMD 0.74
- MACD
- CTO -0.08
- CRMD -0.49
- Stochastic Oscillator
- CTO 42.77
- CRMD 2.42
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.